about our science
Traditional interventions for infectious diseases are centered on the development of vaccines and anti-infectives for prevention and treatment. These approaches have focused a single treatment on a single pathogen (“one drug, one bug”), often diminishing in their efficacy over time due to the emergence of resistance.
Pulmatrix believes it has uncovered a novel approach which will transform the landscape of poorly addressed infectious and progressive respiratory diseases, eliminating the notion of a single pathogen-targeted treatment with broad spectrum, multi-faceted product offerings which will uniquely treat and control respiratory disease. Pulmatrix’s innovative technology is pathogen-independent so it has broad potential to treat a wide range of respiratory diseases, including respiratory infections such as influenza, ventilator acquired pneumonia (VAP) and respiratory syncytial virus (RSV), as well as progressive respiratory diseases such as COPD, asthma, and cystic fibrosis
Pulmatrix’s drugs are uniquely able to deliver this benefit through a dual mechanism of action which enhances and stimulates the inherent biophysical and biochemical properties of the airway:
This unique approach of enhancing the biophysical capabilities of the airway while augmenting host defense mechanisms offers a truly novel approach to treat and prevent infectious and progressive respiratory diseases.
Pulmatrix believes it has uncovered a novel approach which will transform the landscape of poorly addressed infectious and progressive respiratory diseases, eliminating the notion of a single pathogen-targeted treatment with broad spectrum, multi-faceted product offerings which will uniquely treat and control respiratory disease. Pulmatrix’s innovative technology is pathogen-independent so it has broad potential to treat a wide range of respiratory diseases, including respiratory infections such as influenza, ventilator acquired pneumonia (VAP) and respiratory syncytial virus (RSV), as well as progressive respiratory diseases such as COPD, asthma, and cystic fibrosis
Pulmatrix’s drugs are uniquely able to deliver this benefit through a dual mechanism of action which enhances and stimulates the inherent biophysical and biochemical properties of the airway:
- Biological: Pulmatrix’s drugs stimulate host defense mechanisms that prevent infection and enhance the clearance of pathogens.
- Biophysical: Pulmatrix’s drugs activate the assembly of endogenous proteins into three dimensional matrices, resulting in enhanced barrier function in the lung and reducing the penetration of pathogens into the lung tissue. These changes in the rheological properties of the airway further lead to a reduction in the formation and exhalation of infectious biaerosols
This unique approach of enhancing the biophysical capabilities of the airway while augmenting host defense mechanisms offers a truly novel approach to treat and prevent infectious and progressive respiratory diseases.